CIPIH Report could change the lives of neglected patients

[ Geneva – April 5, 2006 ]
DNDi welcomes the final report of the WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). The report clearly states that it is imperative for governments to set global health priorities and promote innovation to develop and deliver much-needed medicines, vaccines, and diagnostics adapted to the needs of the sick and neglected in developing countries.
[Português]

DFID’s funding of DNDi in the news…

[Geneva –March 9, 2005 ]
UK government commits £6.5 million to DNDi’s research for new medicines for neglected diseases
RealHealthNews interview with Bernard Pecoul regarding DFID funding of DNDi.

DNDi Welcomes WHO’s Call to Halt Malaria Monotherapy

[ Geneva , Switzerland – January 20, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the warning issued by the World Health Organization (WHO) to stop selling artemisinin as a monotherapy for malaria, and thus, to prevent the development of resistance to the drug.

DNDi Clinical Trials for Paromomycin begin in Sudan

[ Geneva – November 22, 2004 ]
DNDi‘s first clinical trial site in Um El Kher, Sudan, is up and running. The first patient started treatment on 17 November 2004. Over the next 6 months, 150 patients are expected to join the trial LEAP 0104 at this site managed by Médecins Sans Frontières (MSF) and led by Dr Manica Balasegaram.

The gap is growing: More resources needed now for neglected diseases

[ Geneva – November 11, 2004 ]
Two important conferences convene this month that will decide the future of patients suffering from neglected diseases in the poorer countries of the world: The Ministerial Summit on Health Research, November 16-20 in Mexico City, and the Dutch Government / WHO “Priority Medicines for the Citizens of Europe and the World” meeting, 18 November in The Hague.

Malaria patients enter DNDi clinical trials

[ Geneva – July 2nd, 2004 ]
Millions of people in developing countries still die from diseases neglected by drug development research. A year after its launch, the Drugs for Neglected Diseases Initiative (DNDi) is starting clinical trials for two fixed-dose drug combinations against malaria, and counts another seven projects in the pipeline for sleeping sickness, visceral leishmaniasis and Chagas disease.

New not-for-profit drug research organization born

[ Geneva – July 3rd, 2003 ]
A new not-for-profit drug research organization that will harness cutting-edge science to develop medicines for diseases afflicting the world’s poorest people was established today in Geneva. Prestigious health and research institutes from Brazil, France, India, Kenya and Malaysia joined Médecins Sans Frontières to launch the Drugs for Neglected Diseases initiative (DNDi). DNDi will work in close collaboration with the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR) to achieve its goals.